REG - Convatec Group PLC - Publication of Annual Report and Notice of AGM

ConvaTecAnnouncement

11/03/2025 09:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250311:nRSK0839Aa&default-theme=true

RNS Number : 0839A  Convatec Group PLC  11 March 2025

11 March 2025

Convatec Group Plc

("Convatec" or "the Company")

Annual Report and Accounts 2024 and Notice of Annual General Meeting

 

The Company's annual general meeting (the "Annual General Meeting") will take
place at 14:00 (UK time) on Thursday 22 May 2025 at FGS Global, The Adelphi,
1-11 John Adam Street, London WC2N 6HT.

The Company's Annual Report and Accounts for the year ended 31 December 2024
and the Notice of Annual General Meeting, including details of how
shareholders can appoint a proxy, are being sent to shareholders today and
have been submitted to the National Storage Mechanism in accordance with
paragraph 17.2.1 of the FCA Listing Rules. A copy of the Convatec Group
Omnibus Incentive Plan has also been submitted to the National Storage
Mechanism.  These documents will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

A copy of the Company's Annual Report and Accounts and the Notice of Annual
General Meeting can be accessed on the Company's website at
www.convatecgroup.com (http://www.convatecgroup.com) .

This announcement is made in accordance with DTR 6.3.5R(1A).

 

Enquiries

James Kerton, Company Secretary
 

Tel: +44 (7827) 036059
Email: cosec@convatec.com

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

Classification: 1.1 Annual financial and audit reports

 

 

About Convatec

 

Pioneering trusted medical solutions to improve the lives we touch: Convatec
is a global medical products and technologies company, focused on solutions
for the management of chronic conditions, with leading positions in Advanced
Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than
10,000 colleagues, we provide our products and services in around 90
countries, united by a promise to be forever caring. Our solutions provide a
range of benefits, from infection prevention and protection of at-risk skin,
to improved patient outcomes and reduced care costs. Convatec's revenues in
2024 were over $2 billion. The company is a constituent of the FTSE 100 Index
(LSE:CTEC). To learn more please visit http://www.convatecgroup.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSFLFLTVRIILIE